DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026)

DiaMedica Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 71.36% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 5537.0% year-over-year to 71.36%; the trailing twelve-month figure through Mar 2026 stood at 71.36% (down 5537.0% YoY), and the FY2025 full-year result was 70.59%, down 6243.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 71.36%, down from 63.61% in the prior quarter.
• The five-year high for Return on Capital Employed was 8.31% in Q4 2024, with the low at 71.36% in Q1 2026.
• Historically, Return on Capital Employed has averaged 38.91% across 5 years, with a median of 39.29% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed soared 3278 bps — and 2026, when it sank 5537 bps.
• DiaMedica Therapeutics' Return on Capital Employed stood at 41.73% in 2022, then advanced by 5 bps to 39.85% in 2023, then jumped by 79 bps to 8.31% in 2024, then sank by 665 bps to 63.61% in 2025, then retreated by 12 bps to 71.36% in 2026.
• The last three Return on Capital Employed figures came in at 71.36% (Q1 2026), 63.61% (Q4 2025), and 27.15% (Q3 2025), per Business Quant data.